You are here

Production of Inactivated Virus Vaccines Using Supralethal Irradiation

Award Information
Agency: Department of Defense
Branch: Defense Threat Reduction Agency
Contract: HDTRA1-15-P-0034
Agency Tracking Number: T14B-002-0041
Amount: $149,992.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: DTRA14B-002
Solicitation Number: 2014.2
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-24
Award End Date (Contract End Date): 2016-04-23
Small Business Information
124 Byte drive
Frederick, MD 21702
United States
DUNS: 000000000
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Gregory Tobin
 (301) 378-2135
 tobin@bmi-md.com
Business Contact
 Peter Nara
Phone: (301) 378-2785
Email: nara@bmi-md.com
Research Institution
 Uniformed Services University
 Dr. Michael Daley
 
4301 Jones Bridge Road, C1094
Bethesda, MD 20814
United States

 (301) 295-3450
 Nonprofit college or university
Abstract

We seek a proof-of-concept study for the development of a new platform technology for the rapid and complete inactivation of pathogen infectivity for vaccine development of medically important micro-organisms (e.g. viruses, bacteria and parasites). A recently discovered reconstituted Mn+2-decapeptide phosphate complex (Mn-Dp-Pi) of the radiation-resistant bacterium Deinococcus radiodurans was found to protect proteins bearing antigenic epitopes of a virus from oxidative inactivation at radiation doses which sterilized the virus infectivity. Purified poliovirus in preliminary studies treated via this method were found to be non-infectious while still retaining its natural antigenic make-up as determined by antibody binding. The proposed project intends to expand this initial observation by analyzing the stimulation of virus-neutralizing antibodies in laboratory animals immunized with radiation-inactivated virus preparations. Poliovirus has been selected as the model agent because the factors leading to protective immunity are well understood and a well-characterized vaccine is available for comparison. If successful, the Mn-Dp-Pi -radiation technology would provide the basis for advancement of the technology to later stage TLR readiness thus helping to meet a gap needed for fast and cost effective development and deployment of vaccines against newly emerging pathogens such as Ebola, MERS, SARS, Pandemic Influenza, Enteroviruses, and others of biosecurity interest.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government